GLOBAL PHARMACEUTICAL CONSORTIUM

Following the annihilation of Raccoon City, Umbrella was hit hard with multiple lawsuits for their involvement in the incident. But there was an organization that was hit even harder by the fallout of that incident: the Global Pharmaceutical Consortium, an organization comprised of pharmaceutical companies from around the world.

Umbrellas development of and experimentation with Bio-Organic Weapons (B.O.W.), along with the sale of those weapons on the black market, caused people to distrust the Global Pharmaceutical Consortium, and the fact the Umbrella was an executive board member only deepened their misgivings.

If things had ended there, the consortium may have just escaped with a tarnished reputation. But in today’s world, medicine is an integral part of almost all medical procedures. The public is also quite informed when it comes to which medications are trusted and which are not. If the population loses trust in the pharmaceutical company responsible for creating certain medications, it can quickly bankrupt said company.
The Umbrella trials took a turn for the worse for the consortium when prosecutors presented evidence that incriminated many other pharmaceutical companies.

Prosecutors showed that Umbrella acquired medicines and techniques developed by other companies and employed them in their own bio-weapons research. They commissioned each of the respective companies to only partially develop certain medications so that they could not be traced to what was ultimately being developed. The responsible companies thus unwittingly contributed to the development of bio-weapons.

Until this development in the case, the consortium looked at the lawsuits as Umbrella’s problem. Now the problem was thrust into their laps as well.

The companies that were linked to Umbrella faced the possibility of sharing blame for the deaths of hundreds of thousands of innocent people, and if Umbrella lost the lawsuits, they would face bankruptcy as well. Even if Umbrella was found not guilty of any wrongdoing, the negative publicity would not only be disastrous for sales, but the governments of the world would revoke the companies’ permits to sell their products.
Not having permission to distribute their products worldwide would effectively dismantle their businesses.

The pharmaceutical companies realizes they had no choice but to take drastic measures to counter their dismal prospects.

The consortium decided to strike a deal with the prosecutors. They would put all their efforts into assisting with the case against Umbrella, even to the point of turning over any internal company documentation. The prosecutors in the case, being obsessed with seeing Umbrella fall, agreed to accept the help of the consortium’s companies, and in return they would not pursue legal action against them.

In 2003, Umbrella was found guilty on all charges. With its fall, the scandal that rocked the pharmaceutical industry to its core could finally be put to rest.

But Umbrella’s dismantlement led to an unforeseen situation.

In the fallout of Umbrella’s collapse, B.O.W.s began to show up on the black market. The weapons wound up in the hands of terrorists, guerrilla fighters, and unstable state governments. Soon the thread of these B.O.W.s began to be felt around the world.
Faced with a new Umbrella-like crisis, the Global Pharmaceutical Consortium know they would have to take immediate action.

It was then that the Bioterrorism Security Assessment Alliance (BSAA) was formed to fight threats from B.O.W.s.

Tricell executive Excella Gionne was an official designated officer of the GPC.